PDS Biotechnology Corporation disclosed preliminary data from a National Cancer Institute‑led Phase 2 study of its IL‑12 tumor‑targeted immunocytokine, PDS01ADC, in combination with docetaxel for patients with metastatic castration‑resistant prostate cancer (mCRPC). The data were presented at the American Association of Cancer Research (AACR) special conference on prostate cancer in Boston, MA, held January 20‑22, 2026, and the company announced the results on January 28, 2026.
The study enrolled 16 patients and reported a median progression‑free survival of 9.6 months, with a range of 4.3 to 32.2 months. Median prostate‑specific antigen (PSA) decline was 40 %, and 6 of the 16 patients achieved a PSA reduction greater than 50 %. These figures compare favorably to the typical 3‑ to 4‑month PFS seen with standard third‑line therapies in this population, indicating meaningful anti‑tumor activity.
PDS Biotechnology’s CEO, Frank Bedu‑Addo, emphasized that the results reinforce the potential of the company’s tumor‑targeting IL‑12 platform to enhance the efficacy of existing chemotherapies across solid tumors. The data support the company’s strategy of combining immunocytokines with conventional agents and strengthen the case for advancing PDS01ADC toward regulatory approval.
The positive mCRPC data fit into a broader pipeline that includes PDS0101 for HPV16‑positive head and neck cancers. The Phase 1/2 trial (NCT04633252) is ongoing, with completion expected by the end of 2026, and the new results may accelerate discussions with regulators and potential partners.
While the company remains a cash‑burning, clinical‑stage entity, the encouraging data are likely to bolster investor confidence in its development trajectory and could influence future financing or partnership opportunities.
The Phase 2 results represent a key milestone for PDS Biotechnology, positioning the company for potential future approvals and expanding its portfolio of tumor‑targeted immunotherapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.